卡培他滨联合放疗治疗消化道肿瘤的临床观察

目的：观察卡培他滨联合放疗与单纯放疗治疗消化道恶性肿瘤的疗效。方法：52例有腹腔内可评价病灶的消化道恶性肿瘤病例,分为放疗与卡培他滨联合组（治疗组）26例和单纯放疗组（对照组）26例,治疗组接受腹腔病灶三维适形放疗DT=60-65Gy,同时口服卡培他滨1.5bid共14天,每21天为1周期,共6个周期,对照组只接受腹腔病灶三维适形放疗,DT=60-65Gy,治疗过程中观察毒性反应,放疗结束后2个月评价疗效,观察疾病进展时间（TTP）、1年及2年生存率。结果：治疗组退出试验者3例,可评价病例23例,有效率78.3%（18/23）,对照组有效率61.5%（16/26）,治疗组TTP10个月,对照组5.5个月,P〈0.05,治疗组1年及2年生存率为60.1%和47.8%,对照组为46.2%和19.2%,1年生存率无差异（P〉0.05）,2年生存率有差异（P〈0.05）。结论：卡培他滨同步放疗治疗消化道恶性肿瘤,较单纯放疗能延长疾病进展时间,提高2年生存率,但对有效率、1年生存率无影响。

Clinical Efficacy of Radiotherapy Combined with Capecitabine for Gastrointestinal Tumor

OBJECTIVE：To observe the efficacy of radiotherapy alone or in combination with capecitabine for gastrointestinal tumor.METHODS：52 malignant gastrointestinal tumor cases with evaluable nidus in abdominal cavity were divided into two groups：26 cases in treatment group received three-dimensional radiotherapy（DT = 60-65 Gy） combined with capecitabine（1.5 bid on the first 14 days） for 6 cycles,every cycle consisted of 21 days;and 26 cases in control group received three-dimensional radiotherapy（DT = 60-65 Gy） alone.The toxicity during treatment,the efficacy at 2 months after completion of radiotherapy,the time to progression（TTP） and one-and two-year survival rates were recorded.RESULTS：In the treatment group,3 cases withdrew from the experiment,which left 23 cases under evaluation.The effective rate in the treatment group was 78.3%（18 /23） as compared with 61.5%（16 /26） of the control group.The treatment group had longer median time to progression compared with control group（10 mon vs.5.5 mon,P 0.05）,one-and two-year survival rates were 60.1% and 21.7% in the treatment group versus 46.2% and 23.1% in the control group,showing no significant differences in one-year survival rates（P 0.05） but significant differences were noted in two-year survival rates（P 0.05）.CONCLUSION：Compared with three-dimensional radiotherapy alone,capecitabine combined with three dimensional radiotherapy prolongs the median time to progression and increases two-year survival rates yet without affecting total effect rate and one-year survival rate for patients with gastrointestinal tumor.